-
Mashup Score: 5Impact of Lesion Location on Recurrence After Resection of T1 Colorectal Cancer: Post Hoc Analysis of a Nationwide Multicenter Cohort Study - 3 month(s) ago
T1 colorectal cancer (CRC) can be selectively treated with endoscopic local resection (LR) or surgical resection (SR) by pathologic evaluation of lymph node metastasis (LNM) risk.1–5 In previous studies, LNM frequency was 10%–15% in patients with high-risk lesions.6,7 Consequently, other risk factors require clarification for refined stratification. Regarding lesion location, patients with high-risk T1 rectal cancer have been found to have higher recurrence risk than those with colon lesions in other locations after LR alone.
Source: www.gastrojournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 14AGA Clinical Practice Update on Risk Stratification for Colorectal Cancer Screening and Post-Polypectomy Surveillance: Expert Review - 4 month(s) ago
Since the early 2000s, there has been a rapid decline in colorectal cancer (CRC) mortality, due in large part to screening and removal of precancerous…
Source: www.sciencedirect.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 12
AGA, ACG, ASGE, Fight CRC and more than 90 organizations advocate for improved screening access, policy clarifications from federal agencies.
Source: gastro.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 11Genetic Control of Alternative Splicing and its Distinct Role in Colorectal Cancer Mechanisms - 6 month(s) ago
The comprehensive splicing quantitative trait loci resource highlighted the distinct power of splicing quantitative trait loci signals to uncover the molecular mechanisms of cancer and demonstrated that splicing quantitative trait loci rs61746794 contributed to increased risk of colorectal cancer by promoting the splicing of PRMT7 exon 16, presenting a novel lead for a biologically interpretable paradigm for cancer risk.
Source: www.gastrojournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0
Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Mixed CRC Screening Messaging. Confusing? Some Docs Think So - 7 month(s) ago
Conflicting guidance about when to start CRC screening puts ambiguities about the optimal screening age front and center and has raised concerns among some doctors.
Source: www.medscape.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0CAPOX Regimen Appears Noninferior to FOLFOX in CRC - 7 month(s) ago
The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and Education Award presentation abstract in the August 2023 Journal of the National Comprehensive Cancer Network.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3The OncoAlert Newsletter is NOW OUT Click to Register - 7 month(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The @OncoAlert 🚨Round Up Sept 28 to October 5, 2023 Register at https://t.co/THKFAIOPfb Discussing: ✅Mobocertinib withdrawal: EXCLAIM2🫁 #NSCLC ✅Ovarian Tox in Clinical Trials: @ASCO Statement ✅Anti EGFR Ab🧬in #CRC ✅FASTRACK II:☢️SBRT in #RCC ✅TOP Advances in… https://t.co/fFqM0sAjez https://t.co/HaJwfjCz0g
-
-
Mashup Score: 0
Background Early detection has proven to be the most effective strategy to reduce the incidence and mortality of colorectal cancer (CRC). Nevertheless, most current screening programs suffer from low participation rates. A blood test may improve both the adherence to screening and the selection to colonoscopy. In this study, we conducted a serum-based discovery and validation of cfDNA methylation biomarkers for CRC screening in a multicenter cohort of 433 serum samples including healthy controls, benign pathologies, advanced adenomas (AA), and CRC. Results First, we performed an epigenome-wide methylation analysis with the MethylationEPIC array using a sample pooling approach, followed by a robust prioritization of candidate biomarkers for the detection of advanced neoplasia (AN: AA and CRC). Then, candidate biomarkers were validated by pyrosequencing in independent individual cfDNA samples. We report GALNT9, UPF3A, WARS, and LDB2 as new noninvasive biomarkers for the early detection o
Categories: Future of Medicine, Latest HeadlinesTweet-
Glad to have participated in #colorectal #cancer #CRC screening study using DNA #methylation biomarkers in cell-free DNA #cfDNA of more than 400 samples; article published in Clinical Epigenetics @BioMedCentral led by Loretta De Chiara @cinbio_uvigo @uvigo https://t.co/CqBTwWmd6w https://t.co/NY9gyydutH
-
-
Mashup Score: 7The OncoAlert Newsletter is NOW OUT Click to Register - 7 month(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @OncoAlert: The @OncoAlert 🚨Newsletter Out TOMORROW October 5, 2023 TO Get it REGISTER at https://t.co/yzt83gqQkF Discussing: ✅Moboce…
-
The @OncoAlert 🚨Newsletter Out TOMORROW October 5, 2023 TO Get it REGISTER at https://t.co/yzt83gqQkF Discussing: ✅Mobocertinib withdrawal: EXCLAIM2🫁 #NSCLC ✅Anti EGFR Ab🧬in #CRC ✅Ovarian Tox in Clinical Trials: @ASCO Statement ✅FASTRACK II:SBRT☢️in #RCC #KidneyCancer… https://t.co/Sw0YeOQ7mS https://t.co/UQ7tKZ6KfT
-
Impact of Lesion Location on Recurrence After Resection of T1 #CRC: Post Hoc Analysis of a Nationwide Multicenter Cohort Study ➡️ https://t.co/yDv7kCTCij https://t.co/iJJ9YHoO7X